Azenta (NasdaqGS:AZTA) 2025 Investor Day December 10, 2025 12:45 PM ET Company ParticipantsGinger Zhou - Senior VP and General Manager of the GENEWIZ Multiomics and Synthesis SolutionsMatt Stanton - Managing DirectorAlex Esmon - VP of Cryo and StoresLawrence Lin - EVP and CFOJohn Marotta - President and CEOYvonne Perron - VP of FP&A and Investor RelationsMackenzie Strehle - Senior Equity Research AssociateConference Call ParticipantsDavid Saxon - Senior AnalystBrendan Smith - Director and Senior AnalystMatt ...

Company Overview and Strategy - Azenta is uniquely positioned for strong top-line growth, margin expansion, and inorganic growth opportunities[15] - The company estimates a current serviceable addressable market (SAM) of approximately $6 billion across SMS and Multiomics[18] - Azenta's FY25 revenue was $594 million, with approximately 55% recurring revenue and 3% organic year-over-year growth[26] Sample Management Solutions (SMS) - SMS FY'25 revenue was approximately $325 million, with approximately 50% recurring revenue[85] - The SMS business has experienced a 15%+ CAGR in sample storage growth from FY'15 to FY'25[85] - The company estimates SMS has approximately 11% market share of a $3 billion serviceable addressable market[18, 88] Multiomics (GENEWIZ) - Multiomics (GENEWIZ) FY'25 revenue was approximately $269 million, with over 70% of revenue from returning customers[132] - The company estimates Multiomics has approximately 9% market share of a $3 billion serviceable addressable market[18, 137] - GENEWIZ has sequenced 15 petabytes (PB) of data and synthesized 425 million nucleotides[128] Financial Targets and Capital Allocation - The company is targeting cumulative free cash flow generation of $200 million - $250 million from FY2026 to FY2028[172] - Azenta has a $250 million share repurchase authorization[61] - The company is introducing 2028 organic financial targets including $700 million - $750 million in revenue, 6% - 8% CAGR, 70% recurring revenue, $120 million - $150 million adjusted EBITDA, and 18% - 20% adjusted EBITDA margin[186]

Financial Data and Key Metrics Changes - In Q4 2025, revenue was $159 million, up 6% year-over-year, and up 4% organically, with full-year revenue at $594 million, reflecting a 4% increase on a reported basis and 3% organic growth [14][15] - Non-GAAP EPS for Q4 was $0.21, and $0.51 for the full year, with adjusted EBITDA margin at 13% for Q4 and 11.2% for the full year, representing an expansion of approximately 230 basis points in Q4 and 310 basis points for the full year [14][15] - Free cash flow for the full year was $38 million, a notable improvement of $26 million year-over-year, with $546 million in cash, cash equivalents, and marketable securities at year-end [15][20] Business Line Data and Key Metrics Changes - Sample Management Solutions (SMS) revenue was $86 million for Q4, up 2% reported and flat organically, with a non-GAAP gross margin of 49.3%, up 180 basis points year-over-year [17][18] - Multi-Omix segment delivered record revenue of $73 million in Q4, representing 11% growth on a reported basis and 10% organic growth, driven by a 50% year-over-year increase in sequencing volume [18][19] Market Data and Key Metrics Changes - The macro environment remains volatile, with softer academic and NIH funding impacting growth, particularly in the U.S. market [9][10] - The company anticipates organic revenue growth of 3%-5% for fiscal 2026, with expectations of a decline of approximately 1%-2% in Q1 due to capital expenditure slowdowns and government shutdown impacts [21][60] Company Strategy and Development Direction - The company has implemented the Azenta Business System (ABS) to enhance operational efficiency and accountability, focusing on driving productivity, organic growth, and targeted M&A [8][10] - Strategic priorities include embedding ABS deeper across the organization, optimizing capital deployment, and continuing to deliver core growth and margin expansion [11][21] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating macroeconomic uncertainties and highlighted opportunities arising from customers consolidating partners and investing in automation [9][10] - The company is well-positioned for fiscal 2026, with a focus on operational excellence and a strong balance sheet to support growth initiatives [11][22] Other Important Information - The results exclude B Medical Systems, which is treated as discontinued operations, with an additional non-cash loss of $4 million recorded in Q4 [13] - The company plans to host an Investor Day to outline its multi-year growth strategy and capital deployment priorities [11][21] Q&A Session Summary Question: Guidance on growth expectations and market conditions - Management noted that the market is expected to grow at 1-2%, with capital expenditure slowdowns impacting growth, particularly in the U.S. [25][26] Question: Update on SMS growth and backlog - Confidence in mid-single-digit growth for SMS is supported by a strong backlog and recent investments in commercial initiatives [29][30] Question: Insights on macroeconomic trends affecting customer bases - Management highlighted strength in pharma spending, with some projects being put on hold but showing signs of recovery [38][40] Question: Expectations for M&A activity - The company is focused on tuck-in acquisitions to expand its core business, particularly in SRS and automated solutions [69][70]

Financial Data and Key Metrics Changes - In Q4 2025, revenue was $159 million, up 6% year-over-year and up 4% organically, with full-year revenue at $594 million, reflecting a 4% increase on a reported basis and 3% organically [12][14] - Non-GAAP EPS for Q4 was $0.21, and for the full year, it was $0.51, with adjusted EBITDA margin at 13% for Q4 and 11.2% for the full year, representing an expansion of approximately 230 basis points in Q4 and 310 basis points for the full year [13][14] - Free cash flow for the full year improved by $26 million year-over-year, totaling $38 million, with $546 million in cash, cash equivalents, and marketable securities at year-end [14][19] Business Line Data and Key Metrics Changes - Sample Management Solutions (SMS) revenue was $86 million for Q4, up 2% reported and flat organically, with a non-GAAP gross margin of 49.3%, up 180 basis points year-over-year [16] - Multi-Omix segment achieved record revenue of $73 million in Q4, representing 11% growth on a reported basis and 10% organic growth, driven by a 50% year-over-year increase in sequencing volume [17] - Overall, Multi-Omix gross margin for Q4 was 43.7%, down 260 basis points year-over-year, primarily due to product mix and lower volume in certain areas [18] Market Data and Key Metrics Changes - The macro environment remains volatile, with softer academic and NIH funding impacting growth, particularly in the U.S. market [8][9] - The company anticipates organic revenue growth of 3%-5% for fiscal 2026, with Multi-Omix expected to deliver low single-digit growth and SMS contributing mid-single-digit growth [20][21] Company Strategy and Development Direction - The company has implemented the Azenta Business System (ABS) to enhance operational efficiency and accountability, focusing on driving productivity, organic growth, and targeted M&A [6][7] - The strategic focus includes reinvesting savings into innovation, sales, marketing, and product management, with a commitment to operational excellence and value creation [7][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating macroeconomic uncertainties and highlighted opportunities arising from customer consolidation and outsourcing trends [9][10] - The company is entering fiscal 2026 from a position of strength, with a clear focus on core growth and margin expansion, despite anticipated challenges in the first half of the year [10][21] Other Important Information - The results exclude B Medical Systems, which is treated as discontinued operations, with an additional non-cash loss of $4 million recorded in Q4 [11] - The company plans to host an Investor Day to outline its multi-year growth strategy and capital deployment priorities [10][21] Q&A Session Summary Question: Guidance on growth expectations and market conditions - Management noted that the macroeconomic slowdown and capital expenditure constraints are impacting growth, particularly in the U.S., with expectations of a 1-2% market growth [24][25] Question: Update on SMS growth and backlog - Confidence in mid-single-digit growth for SMS is supported by a strong backlog and recent commercial investments [29][30] Question: Insights on customer spending trends - Management highlighted strength in pharma spending, with some projects being reactivated post-restructuring [36] Question: Clarification on multi-omics growth expectations - Multi-Omix is expected to normalize to mid-single-digit growth due to price and volume adjustments [38] Question: M&A strategy and focus areas - The company is looking at tuck-in acquisitions to expand its core business, particularly in SRS and automated solutions [63][64]

Conference Call Fiscal Fourth Quarter and Full Year 2025 Financial Results November 21, 2025 © 2025 Azenta, Inc. • All rights reserved 1 1 Safe Harbor Statement "Safe Harbor" Statement under the U.S. Private Securities Litigation Reform Act of 1995; certain matters in this presentation, including forecasts of future demand and future Company performance, are forward- looking statements that are subject to risks and uncertainties that could cause actual results to materially differ, either better or worse, f ...

Core Viewpoint - Azenta, Inc. reported a transformative fiscal year 2025 with significant revenue growth and margin expansion, positioning the company for continued growth in fiscal 2026 [3][5]. Financial Performance - For Q4 2025, revenue from continuing operations was $159 million, a 6% increase year-over-year, with organic growth of 4% [2][6]. - Full year revenue for fiscal 2025 reached $594 million, up 4% year-over-year, with organic revenue growth of 3% [2][6]. - Adjusted EBITDA for Q4 2025 was $21 million, representing a 29% increase from the previous year, with an adjusted EBITDA margin of 13.0% [2][6]. - The company achieved a diluted EPS from continuing operations of $1.11 for Q4 2025, compared to a loss of $0.04 in the same quarter last year [2][6]. Segment Performance - Sample Management Solutions generated $86 million in revenue for Q4 2025, a 2% increase year-over-year, while Multiomics revenue was $73 million, up 11% year-over-year [2][6]. - For the full year, Sample Management Solutions revenue was $325 million, a 2% increase, and Multiomics revenue was $269 million, up 6% year-over-year [2][6]. Management Insights - The CEO highlighted the company's streamlined structure and focus on customer needs, projecting core growth of 3% to 5% and approximately 300 basis points of adjusted EBITDA margin expansion for fiscal 2026 [3][5]. - The company emphasized improvements in quality, delivery, and productivity as key drivers of its recent success [3]. Cash and Liquidity - As of September 30, 2025, Azenta had a total balance of cash, cash equivalents, restricted cash, and marketable securities amounting to $546 million [2][6]. Guidance - Azenta expects organic revenue growth for fiscal 2026 to be in the range of 3% to 5%, along with an anticipated adjusted EBITDA margin expansion of approximately 300 basis points [5][6].

Financial Data and Key Metrics Changes - Organic revenue grew by 6% year over year, with adjusted EBITDA margin expanding by 400 basis points [7][26][28] - Total revenue for the second quarter was $143 million, reflecting a 5% year-over-year increase on a reported basis and 6% on an organic basis [27][29] - Non-GAAP EPS for the quarter was $0.05, with adjusted EBITDA margin at 10% [28][29] Business Line Data and Key Metrics Changes - Sample Management Solutions (SMS) revenue was $80 million, up 8% year over year, driven by strong performance in sample repository solutions and core products [30] - Multiomics revenue was $64 million, with a growth of 2% on a reported basis and 3% on an organic basis, primarily driven by next-generation sequencing, which grew 20% year over year [31][32] Market Data and Key Metrics Changes - North America experienced a general slowdown, with an 18% year-over-year decline in Sanger sequencing, while China showed strength with 5% organic revenue growth [34][32] - The company noted a decline in gene synthesis revenue by 10% year over year, attributed to a difficult comparison against a strong prior year [33] Company Strategy and Development Direction - The company is focused on operational excellence and reducing complexity through the Azenta Business System, which aims to enhance problem-solving capabilities and align with strategic goals [12][13] - There is an emphasis on potential tuck-in acquisitions to accelerate revenue growth and margin expansion, alongside investments in digital capabilities [11][12] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the uncertain macro environment, including NIH funding cuts and geopolitical tensions, but expressed confidence in the company's ability to counteract these challenges [9][10] - The company reaffirmed its full-year guidance for organic revenue growth between 3% and 5% and adjusted EBITDA margin expansion of 300 basis points [36][37] Other Important Information - The company has $540 million in cash and cash equivalents, with no debt outstanding, positioning it well for potential acquisitions and capital deployment [11][36] - A non-cash loss of $24 million was recorded on assets held for sale related to B Medical Systems, which is now treated as discontinued operations [25] Q&A Session Summary Question: Guidance and Growth Cadence - Management indicated that the guidance remains unchanged despite a 1% impact from NIH funding, with expectations for the second half of the year to align with prior years [41][44] Question: NIH Funding Headwind - The company has implemented countermeasures to mitigate the 1% headwind from NIH funding, with a focus on outsourcing opportunities as less efficient labs may close [52][57] Question: Free Cash Flow and Margins - Free cash flow performance was strong, and the company remains optimistic about achieving its long-term target of $100 million in free cash flow [58][60] Question: Sales Force Structure - The company is early in the rollout of the Azenta Business System and has aligned its sales force regionally to improve performance [65] Question: Gene Synthesis Trends - Management noted a pause in large programs from pharma partners but observed positive trends in bookings for the current quarter [78][80] Question: Capital Deployment Preferences - The company is open to various capital deployment strategies, including M&A and share buybacks, with a focus on long-term shareholder value [84][86]

Financial Performance - Azenta's Q2 2025 revenue reached $143 million, demonstrating a 5% year-over-year (YoY) growth on a reported basis and 6% on an organic basis[10] - The company's Non-GAAP EPS stood at $005[10] - Adjusted EBITDA was reported at 100%, reflecting a 400 bps YoY margin expansion[10,11] - Free cash flow generation amounted to $7 million, inclusive of B Medical[10] Segment Performance - Sample Management Solutions (SMS) experienced an 8% YoY organic growth[10,16] - Multiomics segment saw a 3% YoY organic growth[10,14] - Within SMS, Consumables and Instruments (C&I) showed a significant 22% growth[20] - Next-Generation Sequencing (NGS) within Multiomics grew by 20%, driven by double-digit volume growth[21] Balance Sheet and Cash Flow - The company holds a strong cash balance of $540 million, including B Medical, with no outstanding debt[10] - Cash flow from operations was $14 million[32] Fiscal Year 2025 Guidance - The company anticipates organic revenue growth of 3% to 5% YoY for fiscal year 2025[38] - Expects 300bps of Adjusted EBITDA margin expansion[39]

Core Insights - The company reported a total revenue of $143 million for the quarter ended March 31, 2025, reflecting a 5% increase year-over-year, driven by growth in Sample Management Solutions and Multiomics [2][7] - The diluted EPS from continuing operations was $(0.40), compared to $(0.29) in the same quarter of the previous year, indicating a significant loss [2][24] - The company has a strong cash position with total cash, cash equivalents, and marketable securities amounting to $540 million as of March 31, 2025 [14] Financial Performance - Revenue from continuing operations was $143 million, down 3% from the previous quarter but up 5% year-over-year [2][7] - Organic revenue growth was 6% year-over-year, with Sample Management Solutions revenue at $80 million, up 8% year-over-year [2][7] - Adjusted EBITDA for continuing operations was $14 million, with an adjusted EBITDA margin of 10.0%, an improvement of 400 basis points year-over-year [2][7] Management Commentary - The CEO highlighted the company's strong performance amidst a challenging macroeconomic environment, emphasizing the resilience of the portfolio and the commitment of the teams [3] - The management expressed confidence in the company's positioning and disciplined operations while navigating uncertainties [3] Cash Flow and Guidance - Operating cash flow for the quarter was $14 million, with capital expenditures of $7 million, resulting in free cash flow of $7 million [14] - The company reiterated its revenue guidance for fiscal year 2025, expecting total organic revenue growth in the range of 3% to 5% compared to fiscal 2024 [14]